Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
EASD 2024: PolTREG's T cell therapy shows long-term remission in type 1 diabetes
PolTREG's PTG-007 cell therapy showed clinical remission for type 1 diabetes up to 12 years post-treatment, prompting plans for a Phase II/III trial and partnership funding.
Late-Stage Alzheimer's Pipeline Goes Beyond Amyloid and Tau
Eisai and Biogen's Leqembi and Eli Lilly's Kisunla are first anti-amyloid antibodies to slow Alzheimer's cognitive decline. 32 therapeutics in Phase III trials target neuroprotection, neurotransmitters, neurogenesis, inflammation, and proteinopathies. Leqembi and Kisunla have limited efficacy and notable side effects, prompting diverse opinions on clinical benefit. Next-gen therapeutics aim for easier administration and multiple pathways to treat Alzheimer's.
Related Clinical Trials:
Should You Follow Insider Buying on This Biotech Penny Stock?
AbCellera Biologics (ABCL) offers high-risk, high-reward potential for investors, with a market cap of $714.5 million. The biotech company specializes in antibody drug discovery using AI and machine learning, positioning it at the forefront of the sector. Despite a 56% decline over the past 52 weeks, CEO Carl Hansen's recent purchase of 283,516 shares signals optimism. Strategic partnerships with Biogen and Eli Lilly enhance AbCellera's influence, and analysts forecast a 459% premium over current levels.
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Leqembi, an Alzheimer's drug from Biogen and Eisai, offers early-stage patients more independent living time but faces hurdles like reimbursement issues, diagnostic tests, and neurologist availability. Missie Meeks, an early recipient, reports improved daily functioning. Despite risks like brain swelling and bleeding, some patients find the process worth it for extended normal life.
Leqembi could give Alzheimer's patients more time, but road to treatment is long
Leqembi, an Alzheimer's drug from Biogen and Eisai, promises to extend patients' normal, independent lives, though it's not a cure. Missie Meeks, diagnosed with early Alzheimer's, benefits from Leqembi, which moderately slows cognitive decline. However, the drug's rollout faces challenges like insurance hurdles and limited neurologist availability. Despite risks of brain swelling and bleeding, some patients find the process worth it for extended quality time with loved ones.
Athira Pays Price as Alzheimer's Candidate Fails Trial
Athira Pharma's lead candidate, fosgonimeton, failed Phase II/III LIFT-AD trial for Alzheimer's, causing a 81% stock drop. Despite missing primary and secondary endpoints, Athira remains committed to fosgonimeton's development, citing potential benefits in specific subgroups. Full data will be presented at the CTAD Conference in Madrid.
Related Clinical Trials:
Higher Spinraza Dose Shows Better Efficacy in Phase II/III Trial
A higher dose of Biogen’s SMA drug Spinraza met primary endpoint in infants, showing significant motor function improvement. The higher dose regimen includes faster loading and higher maintenance doses, well-tolerated with fewer adverse events. Biogen plans to seek regulatory approval for this dose.
Related Clinical Trials:
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
The article discusses the implementation of a Server-Side Rendering (SSR) service entry, identified by the file path '/bundles/v1/views/latest/SSR-service-entry.faddf6530eb1c5019ffb.js'.
Nusinersen Shows Efficacy Compared to Sham Treatment at Experimental Higher Dose
Biogen's nusinersen (Spinraza) showed efficacy at a higher dose than the FDA-approved regimen in the DEVOTE trial, with significant improvements on the CHOP-INTEND scale compared to a sham treatment. The higher dose was generally well-tolerated, though more serious adverse events were observed. Biogen plans to share detailed results with the SMA community and health authorities.
Related Clinical Trials:
© Copyright 2025. All Rights Reserved by MedPath